A Look Inside HIV Resistance through Retroviral Protease Interaction Maps
暂无分享,去创建一个
Peteris Prusis | Jarl E. S. Wikberg | Jan Komorowski | Ramona Petrovska | Aleksejs Kontijevskis | Sviatlana Yahorava | Felikss Mutulis | Ilze Mutule | P. Prusis | J. Komorowski | Sviatlana Yahorava | R. Petrovska | F. Mutulis | J. Wikberg | A. Kontijevskis | I. Mutule
[1] Peteris Prusis,et al. Proteochemometrics: A Tool for Modeling the Molecular Interaction Space , 2005 .
[2] J. Louis,et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.
[3] Irene T Weber,et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. , 2002, European journal of biochemistry.
[4] Irene T. Weber,et al. Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity* , 1997, The Journal of Biological Chemistry.
[5] J. Louis,et al. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.
[6] I. Weber,et al. Comparative Studies on the Substrate Specificity of Avian Myeloblastosis Virus Proteinase and Lentiviral Proteinases (*) , 1996, The Journal of Biological Chemistry.
[7] J. Leis,et al. Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation , 1997, Journal of virology.
[8] A Wlodawer,et al. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. , 1992, The Journal of biological chemistry.
[9] J. Louis,et al. Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. , 1999, European journal of biochemistry.
[10] Arthur J. Olson,et al. Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease , 2000, Journal of Virology.
[11] I. Wakeling,et al. A test of significance for partial least squares regression , 1993 .
[12] Zachary Q. Beck,et al. Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases , 2001, Journal of Virology.
[13] W. Farmerie,et al. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. , 1996, Virology.
[14] B. Dunn,et al. Aspartic Peptidase Inhibitors: Implications in Drug Development , 2003, Critical reviews in biochemistry and molecular biology.
[15] M. Lindgren,et al. Investigation of an allosteric site of HIV-1 proteinase involved in inhibition by Cu2+. , 1998, Advances in experimental medicine and biology.
[16] E. Freire,et al. Designing drugs against heterogeneous targets , 2002, Nature Biotechnology.
[17] S. Wold. Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .
[18] J. Randolph,et al. Peptidomimetic inhibitors of HIV protease. , 2004, Current topics in medicinal chemistry.
[19] L. Polgár,et al. Rate-determining Steps in HIV-1 Protease Catalysis , 1996, The Journal of Biological Chemistry.
[20] I. Weber,et al. Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases (*) , 1995, The Journal of Biological Chemistry.
[21] Peteris Prusis,et al. Prediction of indirect interactions in proteins , 2006, BMC Bioinformatics.
[22] A. Tomasselli,et al. Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. , 1991, The Journal of biological chemistry.
[23] I T Weber,et al. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. , 1994, The Journal of biological chemistry.
[24] I. Weber,et al. Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. , 1993, Biochemistry.
[25] D B Evans,et al. Human immunodeficiency virus type‐1 reverse transcriptase and ribonuclease h as substrates of the viral protease , 1993, Protein science : a publication of the Protein Society.
[26] William G. Bardsley,et al. Optimal design for model discrimination using the F-test with non-linear biochemical models. Criteria for choosing the number and spacing of experimental points , 1989 .
[27] Marianne Manchester,et al. Complete mutagenesis of the HIV-1 protease , 1989, Nature.
[28] A Wlodawer,et al. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. , 1993, The Journal of biological chemistry.
[29] E. Freire,et al. Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.
[30] J. Louis,et al. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. , 2000, European journal of biochemistry.
[31] Alexander Wlodawer,et al. Retroviral proteases , 2002, Genome Biology.
[32] Sami Mahrus,et al. Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease , 2002, Journal of Virology.
[33] J. Louis,et al. Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. , 2000, Biochimica et biophysica acta.
[34] K. Chou,et al. Studies on the specificity of HIV protease: An application of Markov chain theory , 1993, Journal of protein chemistry.
[35] A Wlodawer,et al. Programming the Rous Sarcoma Virus Protease to Cleave New Substrate Sequences (*) , 1996, The Journal of Biological Chemistry.
[36] E. De Clercq,et al. Strategies in the design of antiviral drugs , 2002, Nature reviews. Drug discovery.
[37] A Wlodawer,et al. Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.
[38] J. Louis,et al. Structural basis for specificity of retroviral proteases. , 1998, Biochemistry.
[39] Thomas D. Wu,et al. Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.
[40] Irene T Weber,et al. Narrow Substrate Specificity and Sensitivity toward Ligand-binding Site Mutations of Human T-cell Leukemia Virus Type 1 Protease* , 2004, Journal of Biological Chemistry.
[41] John M. Louis,et al. Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase* , 1999, The Journal of Biological Chemistry.
[42] T. Lundstedt,et al. Experimental design and optimization , 1998 .
[43] C. Hutchison,et al. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.
[44] I. Weber,et al. Comparison of inhibitor binding in HIV‐1 protease and in non‐viral aspartic proteases: the role of the flap , 1990, FEBS letters.
[45] A Wlodawer,et al. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. , 1992, The Journal of biological chemistry.
[46] I. Weber,et al. Studies on the role of the S4 substrate binding site of HIV proteinases , 1991, FEBS letters.
[47] Arthur J. Olson,et al. Structural Basis for Distinctions between Substrate and Inhibitor Specificities for Feline Immunodeficiency Virus and Human Immunodeficiency Virus Proteases , 2003, Journal of Virology.
[48] S. Wold,et al. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. , 1998, Journal of medicinal chemistry.
[49] Hugo Kubinyi,et al. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective , 2004 .
[50] A Wlodawer,et al. Structural and biochemical studies of retroviral proteases. , 2000, Biochimica et biophysica acta.
[51] Amalio Telenti,et al. Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[52] Garrett M Morris,et al. Defining HIV-1 protease substrate selectivity. , 2002, Current drug targets. Infectious disorders.
[53] D Norbeck,et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.
[54] R. Shoeman,et al. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[55] T. Lundstedt,et al. Proteo-chemometrics analysis of MSH peptide binding to melanocortin receptors. , 2002, Protein engineering.
[56] K C Chou,et al. Artificial neural network model for predicting HIV protease cleavage sites in protein , 1998 .
[57] B. Efron. Better Bootstrap Confidence Intervals , 1987 .
[58] J. Louis,et al. Effect of substrate residues on the P2' preference of retroviral proteinases. , 1999, European journal of biochemistry.
[59] Arthur J. Olson,et al. Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3 , 2001, Journal of Virology.
[60] Matthew J. Gonzales,et al. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..
[61] A Wlodawer,et al. Mutations that alter the activity of the Rous sarcoma virus protease. , 1992, The Journal of biological chemistry.
[62] Irene T Weber,et al. Combining mutations in HIV‐1 protease to understand mechanisms of resistance , 2002, Proteins.
[63] K. Chou,et al. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method , 1996, Proteins.
[64] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[65] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[66] T. Copeland,et al. Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.
[67] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[68] A Wlodawer,et al. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. , 1998, Biochemistry.